Riviciclib
| CAS No. | 920113-02-6 | Cat. No. | BCP17903 |
| Name | Riviciclib | ||
| Synonyms | P276-00; P-276-00; P 276-00; P-27600; P 27600; P 27600; | ||
| Formula | C21H20ClNO5 | M. Wt | 401.84 |
| Description | Riviciclib, also known as P276-00 , is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. P276-00 selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. | ||
| Pathways | Cell Cycle/DNA Damage | ||
| Targets | CDK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.